Hengrui SHR6390 intends to be included in the breakthrough therapy CDK4/6 inhibitor mixture...

Recently, Hengrui Pharmaceutical's innovative drug SHR6390 tablets was included in the list of proposed breakthrough treatments by the Drug Evaluation Center of the National Medical Products Administration.

Source: CDE

SHR6390 is an oral, high-efficiency and selective small molecule CDK4/6 inhibitor developed by Jiangsu Hengrui, which belongs to the first class of chemical drugs.

Introduction to CDK4/6 Inhibitors

Cyclin Dependent Kinase (CDK) is a key kinase involved in cell cycle regulation.

CDK4/6 inhibitor approval status

In recent years, CDK4/6 inhibitors are rapidly changing the treatment pattern of HR+ and HER2- advanced breast cancer.

Pfizer’s piperacillil no longer leads the way, CDK4/6 inhibitor melee is about to start

As the first CDK4/6 inhibitor drug to be marketed, Pfizer's piperacillil has an obvious first-mover advantage.

It can be said that piperacillil dominates the CDK4/6 inhibitor market, and even if reboxilil and abecilil are listed afterwards, they have not been able to shake its market position.

In fact, on December 18, 2020, Qilu Pharmaceutical's 4 generic drugs, piperacillil capsules, have been approved for marketing by NMPA, which is the first imitation of this variety, and its indication is the first-line combination of aromatase inhibitors to treat postmenopausal patients.

(Source: CDE)

In short, CDK 4/6 is a star target, and many companies are developing innovative drugs in the country.

Reference source:

1.